relatlimab (BMS-986016) / BMS 
Welcome,         Profile    Billing    Logout  
 4 Diseases   49 Trials   49 Trials   1073 News 


12345678910111213...1516»
  • ||||||||||  Review, Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker:  Beyond Checkpoint Inhibition: Keeping Therapeutic Options Open. (Pubmed Central) -  Apr 15, 2025   
    Combination immune checkpoint inhibitor therapy (ICI) with ipilimumab (anti-cytotoxic T-lymphocyte-associated protein 4) + nivolumab (anti-PD-1) in untreated, metastatic melanoma has achieved a ten-year melanoma-specific survival of 52%...Addition of ipilimumab, relatlimab (anti-LAG3), or lenvatinib (VEGFR TKI) has minimal to modest efficacy...Recently, personalized, autologous tumor-infiltrating lymphocyte therapy has become a US Food and Drug Administration-approved second-line option; lifileucel demonstrates durable response (approximately 30%) in heavily pretreated, metastatic melanoma...As a therapy which is limited to patients who are HLA-A*02:01, T-cell receptor (TCR) engineered T cells (TCR-T) iterates on personalized adoptive cell transfer, and immune mobilizing monoclonal TCRs against cancer are CD3 bispecifics that bind glycoprotein 100 (tebentafusp, approved for metastatic uveal melanoma) or PRAME to activate T cells...ICI may be given with modified immunosuppression in patients with autoimmune disease or previous organ transplantation. Cumulative data support safe administration in older patients and in ICI rechallenge for patients with previous irAE.
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Trial completion, Enrollment change, Trial completion date:  CA209-6D9: Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases (clinicaltrials.gov) -  Mar 27, 2025   
    P1,  N=1, Completed, 
    Recruiting --> Active, not recruiting | Trial completion date: May 2026 --> Jun 2030 Active, not recruiting --> Completed | N=16 --> 1 | Trial completion date: Jun 2025 --> Aug 2024
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
    Journal, PD(L)-1 Biomarker, IO biomarker:  Treatment of metastatic melanoma with anti-PD-1 and anti-LAG-3 in a kidney transplant recipient. (Pubmed Central) -  Mar 27, 2025   
    LAG-3 expression was notably positive in the renal graft, but negative in the metastatic melanoma tumor tissue. Although the outcome resulted in rapid renal graft rejection, this underscores the need for further research into LAG-3's dual role in cancer therapy and allograft rejection in organ transplant recipients.
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
    Microscopic colitis - rare events secondary to immune checkpoint inhibitors therapy (Section 34; Poster Board No: 15) -  Mar 25, 2025 - Abstract #AACR2025AACR_7771;    
    MC is suspected to result from increased immune activity in the gut mucosa. It can develop following ICIs therapy and presents with severe symptoms, often requiring hospitalization, steroids, and other immunomodulators.
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Spatially resolved immunologic hallmarks of response to neoadjuvant immune checkpoint blockade in metastatic melanoma (Section 28; Poster Board No: 18) -  Mar 25, 2025 - Abstract #AACR2025AACR_7718;    
    We leveraged cutting-edge spatial -omics technologies and novel computational methods to resolve the immunologic hallmarks of NICB response in metastatic melanoma. We believe our approach will usher in a new paradigm for the investigation of other cancer biospecimens in the new era of standard of care neoadjuvant immunotherapy.
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Unravelling the mechanisms of resistance and hyperprogression of renal medullary carcinoma to immune checkpoint therapy (Section 28; Poster Board No: 12) -  Mar 25, 2025 - Abstract #AACR2025AACR_2818;    
    P2
    IACS16898 treatment significantly reduced the expression of myeloid-associated markers on GFP+ tumor cells. Our study not only elucidates a novel mechanism of resistance and hyperprogression to PD1 plus either CTLA4 or LAG3 inhibition in SMARCB1-deficient cancers but also provides a foundation for targeting oncogenic and resistance pathways in RMC treated with distinct immunotherapy regimens.
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
    Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker:  Immunologic correlates in a CIC::DUX4 fusion-positive sarcoma responsive to dual immune checkpoint blockade. (Pubmed Central) -  Mar 25, 2025   
    This case provides the first evidence of dual PD-1/LAG-3 blockade inducing an immune response in CDS. The favorable response and tolerability observed in this patient highlight the potential of dual ICB as a therapeutic option in CDS that merits further investigation.
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
    Biomarker, Trial completion, Trial completion date:  Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer (clinicaltrials.gov) -  Jan 28, 2025   
    P2,  N=59, Completed, 
    Further efforts at European and global levels are needed to harmonize and enhance access to cancer medicines. Active, not recruiting --> Completed | Trial completion date: Feb 2025 --> Sep 2024
  • ||||||||||  IMA203 / Immatics
    Enrollment open:  SUPRAME-ACTengine (clinicaltrials.gov) -  Jan 17, 2025   
    P3,  N=360, Recruiting, 
    Given the potential severity of myocarditis, myositis, and myasthenia gravis-like syndrome, immediate corticosteroid treatment is recommended upon suspicion, without awaiting a confirmed diagnosis. Not yet recruiting --> Recruiting
  • ||||||||||  IMA203 / Immatics
    New P3 trial:  SUPRAME-ACTengine (clinicaltrials.gov) -  Dec 19, 2024   
    P3,  N=360, Not yet recruiting, 
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
    Trial completion date, Trial primary completion date:  CA224-094: Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma (clinicaltrials.gov) -  Dec 5, 2024   
    P2,  N=27, Active, not recruiting, 
    Treatment with nivolumab-relatlimab could be preferred as a combination ICI given the lower incidence of severe irAEs, delayed onset of irAEs, and lower rate of treatment discontinuation. Trial completion date: Dec 2026 --> Jan 2026 | Trial primary completion date: Dec 2024 --> Jan 2024
  • ||||||||||  Review, Journal, Checkpoint inhibition:  Immune Checkpoint Inhibitor Myopathy: The Double-Edged Sword of Cancer Immunotherapy. (Pubmed Central) -  Nov 15, 2024   
    Despite clinical improvements with immunomodulatory therapy, with corticosteroids the mainstay of treatment, mortality remains high, particularly in those with associated myocarditis or respiratory failure requiring intubation, where mortality occurs in up to 50%. ICI withdrawal can lead to cancer progression and death, highlighting a need for improved approaches to ICI rechallenge, performed in limited patients with variable success to date.